Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-AP1M2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
AP1M2 or Adaptor Protein Complex 1 Mu 2 Subunit is an essential component of the adaptor protein complex involved in clathrin-mediated endocytosis. It exhibits a molecular weight of approximately 47 kDa. AP1M2 is ubiquitously expressed in human tissues with prominent expression in the brain liver and kidney. Its role as a cytosolic protein links it to cellular transport and sorting mechanisms.
Biological function summary
AP1M2 interacts with other subunits to form the AP-1 complex a critical assembly for sorting lysosomal enzymes and trans-Golgi network system function. The AP-1 complex directs the budding of vesicles by interacting with clathrin and cargo membrane proteins. These interactions ensure proper intracellular trafficking contributing to the maintenance of cellular homeostasis. AP1M2’s interactions within the complex indicate its indispensable role in proper membrane protein sorting.
Pathways
AP1M2 contributes significantly to the endocytic pathway and protein transport processes. It is active within the clathrin-mediated endocytosis pathway working closely with proteins such as AP1B1 and AP1G1. These partnerships facilitate the transport of essential molecules from the trans-Golgi network to endosomes and lysosomes influencing cell signaling and nutrient uptake.
AP1M2's dysfunction relates to neurodegenerative conditions such as Alzheimer’s disease where disruptions in protein sorting and trafficking are common. It also connects to lysosomal storage disorders as abnormalities in the AP-1 complex affect lysosome function and enzyme transport. AP1M2 through its roles and associations suggests its involvement alongside other proteins such as APP and lysosomal enzymes in disease mechanisms.
